Syra Health Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026, disclosing unaudited financial statements and management discussion for the three and nine months ended September 30, 2026.

Key Highlights

  • Total assets of $4,225,390 as of September 30, 2026, compared to $2,772,917 as of December 31, 2025, according to the filing.
  • Cash and cash equivalents of $2,383,413 as of September 30, 2026, up from $1,614,733 at December 31, 2025.
  • Accounts receivable, net, of $1,517,493 as of September 30, 2026, compared to $918,374 at December 31, 2025.
  • Total liabilities of $1,201,696 as of September 30, 2026, up from $674,739 at December 31, 2025, the filing stated.
  • Deferred revenue of $261,249 as of September 30, 2026, compared to $16,611 at December 31, 2025.
  • Class A common stock shares outstanding of 13,850,279 as of November 3, 2026, up from 11,339,169 shares at December 31, 2025.
  • Registrant classified as a smaller reporting company and emerging growth company, with a non-accelerated filer designation, as indicated in the filing.

Syra Health's September 2026 Financial Position and Capital Structure

According to the filing, Syra Health Corp. (OTC QB:SYRA), a Delaware corporation headquartered at 1119 Keystone Way N. #201, Carmel, IN 46032, reported total current assets of $4,163,904 as of September 30, 2026, compared to $2,738,530 at December 31, 2025. The increase was driven by growth in cash and cash equivalents and accounts receivable, net, the filing disclosed. Property and equipment, net, stood at $4,476 as of September 30, 2026, down from $6,986 at December 31, 2025.

On the liabilities side, the filing reported accounts payable of $211,169, accounts payable to related parties of $125,000, accrued expenses of $367,996, and notes payable of $179,272 as of September 30, 2026. The current portion of the operating lease liability, related party, was $57,010, with no non-current portion remaining. Total stockholders' equity components included Class A common stock at $0.001 par value with 100,000,000 shares authorized, and convertible Class B common stock at $0.001 par value with 5,000,000 shares authorized and 350,000 shares outstanding as of September 30, 2026, compared to 600,000 at December 31, 2025, according to the partially disclosed balance sheet.

The filing noted that the registrant had not filed all reports required during the preceding 12 months, checking "No" on that compliance indicator. Preferred stock, with 10,000,000 shares authorized, had no shares designated, issued, or outstanding as of either period reported, the filing stated. The company's forward-looking statements, as characterized in the filing, are subject to its cautionary language and involve substantial known and unknown risks and uncertainties.

What Was Disclosed

Syra Health Corp. filed its quarterly report covering the period ended September 30, 2026, disclosing unaudited balance sheets, statements of operations, changes in stockholders' equity, and cash flows for the three and nine months ended September 30, 2026 and 2025.